Table 2.
LMP2, LMP7, TAP1, TAP2, and HLA Class I Antigen Expression in Nevi and in Primary and Metastatic Melanoma Lesions
| Lesions | Score | LMP2 | LMP7 | TAP1 | TAP2 | HLA Class I | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| no. | % | no. | % | no. | % | no. | % | no. | % | ||
| Nevi | + | 6 | (60) | 6 | (60) | 7 | (70) | 5 | (50) | 5 | (50) |
| +/− | 4 | (40) | 4 | (40) | 3 | (30) | 5 | (50) | 2 | (20) | |
| − | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 3 | (30) | |
| Primary | + | 18 | (37) | 27 | (55) | 29 | (48) | 26 | (44) | 25 | (42) |
| +/− | 20 | (41) | 20 | (41) | 19 | (32) | 23 | (38) | 24 | (40) | |
| − | 11 | (22) | 2 | (4) | 12 | (20) | 11 | (18) | 11 | (18) | |
| Metastatic | + | 7 | (19) | 20 | (53) | 5 | (13) | 9 | (24) | 7 | (18) |
| +/− | 21 | (55) | 14 | (37) | 26 | (69) | 21 | (55) | 16 | (42) | |
| − | 10 | (26) | 4 | (10) | 7 | (18) | 8 | (21) | 15 | (40) |
+, positive (>75%); +/−, heterogeneous (25–75%); −, negative (<25%)